| Name | Title | Contact Details |
|---|---|---|
Frederic-Andre Vennat |
Executive Director, Program Management Office Lead, Human Health | Profile |
Jacob Langbein |
Director, Global Marketing | Profile |
Greg Elwood |
Associate Director, US Payer Marketing | Profile |
Ali Guerrieri |
Associate Director Consumer Marketing | Profile |
Anoop Kumar |
Director Financial Systems, Life Science | Profile |
BigHat`s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics.
AltaThera Pharmaceuticals is a Chicago-based specialty pharmaceutical company focused on identifying, acquiring, developing, and commercializing therapies addressing unmet medical needs of critical care patients and those with severe, and often rare, disorders for which few effective treatments are available.
We believe that our Hypermatrix technology is a novel and robust controlled-release drug delivery platform. This unique technology allows us to provide life-cycle management or new chemical entity delivery system solutions for virtually any small molecule. The flexibility of this technology allows us to quickly develop complex drug delivery solutions.
Tenami Pharmaceuticals Inc is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.